Last reviewed · How we verify
NCT04943978
Prospective Studies on Immunopathogenesis of Liver Fibrosis
trial in Chronic Liver Disease in 1,000 participants. Status unknown.
31 January 2023
Quick facts
| Lead sponsor | University of Regensburg |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 February 2014 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across Germany |
Conditions studied
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
Sponsor
University of Regensburg
Who can join
18 and older, any sex, with Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The immune system is thought to play a key role in the development of liver inflammation and subsequent liver fibrosis or cirrhosis. In the case of viral hepatitis and autoimmune hepatitis, for example, numerous studies have focused on the acquired antigen-specific immunity. However, the liver is the site of increased occurrence of the components of the innate immune response (NK and NKT cells) and, in contrast to T cells, these T cells, these do not require antigen presentation. Therefore, the present study was designed to determine which cellular components of the (NK, NKT, dendritic cells, macrophages) or the acquired immune response (CD4, CD8) or which network of immune cells is involved in the immunopathogenesis of progressive liver inflammation or the development of liver fibrosis. The aim is to identify lymphocyte populations that exhibit either prognostically favorable or unfavorable characteristics. This should allow conclusions to be drawn for a more targeted and individualized therapy of the respective chronic liver diseases.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Soluble CD46 as a diagnostic marker of hepatic steatosis.
Bitterer F, Kupke P, Adenugba A, Evert K, et al · · 2024 · cited 5× · PMID 38838471 · DOI 10.1016/j.ebiom.2024.105184 -
Proteolytic shedding of CD46 from human hepatocytes indicates liver stress.
Kupke P, Yang Zhou J, Glehr G, Riquelme P, et al · · 2024 · cited 1× · PMID 39698100 · DOI 10.1016/j.heliyon.2024.e40841 -
Soluble CD46 improves detection of hepatic steatosis by contrast-enhanced computed tomography before liver surgery.
Kupke P, Kupke LS, Glehr G, Evert K, et al · · 2025 · PMID 40277388 · DOI 10.1097/js9.0000000000002422
Verify or expand the search:
- PubMed search for NCT04943978
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Liver Disease
Currently open trials in the same condition.
- NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
- NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
- NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
- NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
- NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting
Other University of Regensburg trials
Trials by the same sponsor.
- NCT07444242 — Accelerated Treatment of Depressive Patients With tDCS · NA · not yet recruiting
- NCT06766214 — Attexis and tDCS for the Treatment of ADHD · NA · completed
- NCT06689592 — Mobile Transcranial Magnetic Stimulation · NA · completed
- NCT06520865 — TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis · completed
- NCT06212895 — Expectations of Patients Regarding Exercise in an Outpatient Clinic · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04943978 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Regensburg
- Last refreshed: 29 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04943978.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing